Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenretinide SCHEMBL4996036 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL839699 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL13402304 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL9838209 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL19121 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL15703189 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL11704 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL10629371 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL11703 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL17593790 | 0.99 | RBP4 (0.98) | RBP4ALDH1A1MAPTHIF1ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9421175-B2 | Prevention of retinopathy by inhibition of the visual cycle | LARSEN LARS MICHAEL (DK) | 2016-08-23 | — | — | US | disclosed |
| EP-1727529-B1 | PREVENTION OF RETINOPATHY BY INHIBITION OF THE VISUAL CYCLE | LARSEN LARS MICHAEL (DK) | 2016-03-02 | — | — | EP | disclosed |
| US-20080214668-A1 | USE OF RETINOIDS TO TREAT HIGH BLOOD PRESSURE AND OTHER CARDIOVASCULAR DISEASE | OREGON HEALTH AND SCIENCES UNIVERSITY (US) | 2008-09-04 | — | — | US | disclosed |
| US-20070249713-A1 | Prevention of Retinopathy by Inhibition of the Visual Cycle | LARSEN LARS M | 2007-10-25 | — | — | US | disclosed |
| US-20070154981-A1 | Insulin-producing cells derived from stem cells | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-07-05 | — | — | US | disclosed |
| WO-2005045001-A2 | INSULIN-PRODUCING CELLS DERIVED FROM STEM CELLS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2005-05-19 | — | — | WO | disclosed |
| US-20030008919-A1 | Use of retinoids to treat high blood pressure and other cardiovascular disease | ROULLET JEAN-BAPTISTE (US) | 2003-01-09 | — | — | US | disclosed |
| US-6437003-B1 | STROKES | ROULLET JEAN-BAPTISTE (US) | 2002-08-20 | — | — | US | disclosed |
| EP-0261911-B1 | PROCESS FOR PREPARING RETINOYL CHLORIDES | McNeilab, Inc. (US) | 1991-08-21 | — | — | EP | disclosed |
| US-4743400-A | Process for preparing retinoyl chlorides | MCNEILAB, INC. (US) | 1988-05-10 | — | — | US | disclosed |
| EP-0261911-A2 | Process for preparing retinoyl chlorides | McNeilab, Inc. (US) | 1988-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008919-A1 | Use of retinoids to treat high blood pressure and other cardiovascular disease | RARA, RXRA, RARB | RBP4 6/4885ALDH1A1 1261/4885MAPT 2189/4885 |
| US-20070249713-A1 | Prevention of Retinopathy by Inhibition of the Visual Cycle | VEGFA, HIF1AN, ALDH1A2 | RBP4 6/4885ALDH1A1 1458/4885MAPT 2727/4885 |
| US-20080214668-A1 | USE OF RETINOIDS TO TREAT HIGH BLOOD PRESSURE AND OTHER CARDIOVASCULAR DISEASE | RARA, RXRA, RARB | RBP4 6/4885ALDH1A1 1261/4885MAPT 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.